Sign In
Buy MGTA
$0.700
+0 (+0%)
At Close: Dec 08, 2023
Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences
08:30pm, Monday, 08'th Jun 2020
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company wi
Magenta Therapeutics Presents Data Supporting Immune Reset for Autoimmune Diseases
12:30pm, Friday, 05'th Jun 2020
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today reported the presenta
Magenta Therapeutics Presents Data Supporting Immune Reset for Autoimmune Diseases
12:00am, Friday, 05'th Jun 2020
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transp
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of blood and immune reset to more patients, presented preclinical dat
Avrobio Magenta Collaboration, And Other News: The Good, Bad And Ugly Of Biopharma
06:44pm, Thursday, 07'th May 2020
Avrobio and Magenta will collaborate on a novel ADC. Adverum reports positive wet AMD data. AstraZeneca's Farxiga is approved.
Magenta Therapeutics Reports Recent Business Highlights and First Quarter Financial Results
11:30am, Thursday, 07'th May 2020
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today reported recent business high
AVROBIO Reports 1Q 2020 Financial Results and Provides Business Update
12:00am, Thursday, 07'th May 2020
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today re
AVROBIO, Inc. (Nasdaq: AVRO) and Magenta Therapeutics (Nasdaq: MGTA) today announced a research and clinical collaboration agreement to evaluate the potential utility of MGTA-117, Magenta’s novel ta
Magenta Therapeutics to Host Business Update Conference Call
12:00pm, Thursday, 30'th Apr 2020
Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced it will host a confe
Magenta Therapeutics to Present Data from Across Portfolio at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
08:30pm, Tuesday, 28'th Apr 2020
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that data f
Magenta Therapeutics Inc (NASDAQ:MGTA) Shares Purchased by Geode Capital Management LLC
10:14am, Tuesday, 28'th Apr 2020
Geode Capital Management LLC raised its stake in shares of Magenta Therapeutics Inc (NASDAQ:MGTA) by 6.2% in the 4th quarter, according to the company in its most recent filing with the Securities & E
Magenta Therapeutics Names John Davis Jr., M.D., M.P.H, M.S., Head of Research and Development
12:11pm, Friday, 17'th Apr 2020
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that it has promote
Magenta Therapeutics Provides Business Update
12:00pm, Thursday, 16'th Apr 2020
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today provided a current update on
Magenta Therapeutics Inc (NASDAQ:MGTA) Expected to Announce Earnings of -$0.61 Per Share
11:34am, Sunday, 12'th Apr 2020
Equities analysts predict that Magenta Therapeutics Inc (NASDAQ:MGTA) will announce earnings of ($0.61) per share for the current quarter, according to Zacks Investment Research. Zero analysts have is
We Think Magenta Therapeutics (NASDAQ:MGTA) Can Afford To Drive Business Growth
05:21pm, Tuesday, 07'th Apr 2020
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
